CN100526463C - 利用二价金属离子制备Apo-2配体的方法 - Google Patents

利用二价金属离子制备Apo-2配体的方法 Download PDF

Info

Publication number
CN100526463C
CN100526463C CNB008119589A CN00811958A CN100526463C CN 100526463 C CN100526463 C CN 100526463C CN B008119589 A CNB008119589 A CN B008119589A CN 00811958 A CN00811958 A CN 00811958A CN 100526463 C CN100526463 C CN 100526463C
Authority
CN
China
Prior art keywords
apo
ligand
amino acid
formulation
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB008119589A
Other languages
English (en)
Chinese (zh)
Other versions
CN1370232A (zh
Inventor
阿维·J·阿什克纳兹
萨拉·希莫威茨
罗伯特·F·凯利
伊菲吉妮亚·库米尼斯
苏珊·勒恩格
马克·奥康奈尔
罗杰·佩
扎拉·沙罗克
劳拉·西蒙斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CN1370232A publication Critical patent/CN1370232A/zh
Application granted granted Critical
Publication of CN100526463C publication Critical patent/CN100526463C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB008119589A 1999-06-28 2000-06-26 利用二价金属离子制备Apo-2配体的方法 Expired - Lifetime CN100526463C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14134299P 1999-06-28 1999-06-28
US60/141,342 1999-06-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN200910145880A Division CN101633692A (zh) 1999-06-28 2000-06-26 利用二价金属离子制备Apo-2配体的方法

Publications (2)

Publication Number Publication Date
CN1370232A CN1370232A (zh) 2002-09-18
CN100526463C true CN100526463C (zh) 2009-08-12

Family

ID=22495287

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB008119589A Expired - Lifetime CN100526463C (zh) 1999-06-28 2000-06-26 利用二价金属离子制备Apo-2配体的方法
CN200910145880A Pending CN101633692A (zh) 1999-06-28 2000-06-26 利用二价金属离子制备Apo-2配体的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200910145880A Pending CN101633692A (zh) 1999-06-28 2000-06-26 利用二价金属离子制备Apo-2配体的方法

Country Status (12)

Country Link
US (3) US7855066B1 (enExample)
EP (3) EP1194555B1 (enExample)
JP (2) JP5118796B2 (enExample)
KR (1) KR100674528B1 (enExample)
CN (2) CN100526463C (enExample)
AU (3) AU6338200A (enExample)
CA (1) CA2377585A1 (enExample)
ES (1) ES2392392T3 (enExample)
IL (2) IL147029A0 (enExample)
MX (1) MXPA01013236A (enExample)
NZ (2) NZ515990A (enExample)
WO (1) WO2001000832A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020106728A1 (en) * 2000-06-20 2002-08-08 Genentech, Inc. NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
EP1820860A3 (en) * 1999-06-02 2008-03-19 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
EP1194555B1 (en) * 1999-06-28 2012-09-26 Genentech, Inc. Methods for making apo-2 ligand using divalent metal ions
EP2348043A1 (en) * 2001-10-02 2011-07-27 Genentech, Inc. APO-2 ligand variants and uses thereof
CA2466054C (en) 2001-11-13 2012-01-03 Genentech, Inc. Apo-2 ligand/trail formulations
AU2007200478A1 (en) * 2001-11-13 2007-02-22 Genentech, Inc. APO2 ligand/trail formulations
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
US7741285B2 (en) * 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
WO2004001009A2 (en) * 2002-06-24 2003-12-31 Genentech, Inc. Apo-2 ligand/trail variants and uses thereof
GB0328261D0 (en) * 2003-12-05 2004-01-07 Univ Groningen Improved cytokine design
BRPI0507233B8 (pt) 2004-03-11 2021-05-25 Genentech Inc processo para a produção de um polipeptídeo heterólogo em e. coli
CN101061238B (zh) 2004-08-06 2013-11-20 健泰科生物技术公司 使用生物标志的测定法和方法
ES2365719T3 (es) 2004-08-06 2011-10-10 Genentech, Inc. Ensayos y procedimientos que utilizan biomarcadores.
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
BRPI0615997A8 (pt) 2005-08-16 2018-05-22 Genentech Inc método para prever a sensibilidade de uma amostra de célula ou tecido, método para induzir apoptose em uma amostra de célula ou tecido e método de tratamento de uma disfunção
GB0524316D0 (en) * 2005-11-29 2006-01-04 Medical Res Council Tumour necrosis factor-related apoptosis-inducing ligands (TRAILs)
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
WO2012151317A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Vascular disruption agents and uses thereof
CN102775491A (zh) * 2011-05-09 2012-11-14 中国人民解放军第二军医大学 单链化的人凋亡素2配体三聚体蛋白质的制法和用途
CN102443055B (zh) * 2011-10-26 2017-07-28 浙江海正药业股份有限公司 一种重组人肿瘤坏死因子相关凋亡诱导配体的纯化工艺
JP6355425B2 (ja) * 2014-05-20 2018-07-11 キヤノン株式会社 システムおよびその制御方法
US11279768B1 (en) 2015-04-03 2022-03-22 Precision Biologics, Inc. Anti-cancer antibodies, combination therapies, and uses thereof
US10906951B2 (en) * 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
AU2017234679A1 (en) * 2016-03-16 2018-08-30 Merrimack Pharmaceuticals, Inc. Engineered trail for cancer therapy
JP7257345B2 (ja) * 2019-04-04 2023-04-13 株式会社オハラ 光学ガラスの製造方法
JP7429622B2 (ja) * 2020-08-26 2024-02-08 株式会社オハラ 光学ガラスの製造方法
CN115980241B (zh) * 2023-02-11 2025-01-07 烟台新特路新材料科技有限公司 一种硫代酯类抗氧化剂含量的检测方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997001633A1 (en) * 1995-06-29 1997-01-16 Immunex Corporation Cytokine that induces apoptosis
WO1997023615A1 (de) * 1995-12-22 1997-07-03 Boehringer Mannheim Gmbh Multimere formen von il-16, verfahren zu ihrer herstellung und verwendung
WO1997025428A1 (en) * 1996-01-09 1997-07-17 Genentech, Inc. Apo-2 ligand

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
ES2032831T5 (es) 1986-08-19 2001-02-16 Genentech Inc Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas.
JPH04501201A (ja) 1987-12-21 1992-03-05 ジ・アップジョン・カンパニー 発芽植物種子類のアグロバクテリウム媒介形質転換
US6063763A (en) * 1989-04-28 2000-05-16 Schering Aktiengesellschaft Protease-resistant thrombomodulin analogs
DK168302B1 (da) 1989-06-29 1994-03-07 Danisco Fremgangsmåde til indføring af molekyler, især genetisk materiale i planteceller
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
WO1992003478A1 (en) 1990-08-17 1992-03-05 Genentech, Inc. Metal ion mediated receptor binding of polypeptide hormones
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
WO1992017200A2 (en) 1991-03-28 1992-10-15 Genentech, Inc. Stable growth hormone metal ion formulations
US6387650B1 (en) * 1995-06-07 2002-05-14 Biocontrol Systems, Inc. Method and composition for detecting bacterial contamination in food products
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
AU3381097A (en) 1996-06-07 1998-01-05 Amgen, Inc. Tumor necrosis factor-related polypeptide
WO1998014577A2 (en) 1996-10-03 1998-04-09 Biotherapies, Inc. Nucleotide and protein sequence of mammastatin and methods of use
NZ334309A (en) 1996-10-25 2000-08-25 Human Genome Sciences Inc Neutrokine alpha protein, a member of the TNF family, and its use in treating and/or detecting immune disorders
ATE497001T1 (de) 1996-12-23 2011-02-15 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
EA003636B1 (ru) 1997-04-16 2003-08-28 Амген Инк. Остеопротегеринсвязующие белки и рецепторы
PT981618E (pt) 1997-05-15 2007-11-23 Genentech Inc ''anticorpo anti-apo-2''
AU8485098A (en) 1997-08-26 1999-03-16 Genentech Inc. Rtd receptor
CA2318029C (en) * 1998-01-15 2009-05-19 Genentech, Inc. Apo-2 ligand
SE9802454D0 (sv) 1998-07-08 1998-07-08 Pharmacia & Upjohn Ab Production of peptides
EP1194555B1 (en) * 1999-06-28 2012-09-26 Genentech, Inc. Methods for making apo-2 ligand using divalent metal ions
AU7053000A (en) 1999-09-10 2001-04-10 Eli Lilly And Company Flint compounds and formulations thereof
AU6891800A (en) 1999-09-10 2001-04-10 Eli Lilly And Company Flint analog compounds and formulations thereof
EP2348043A1 (en) * 2001-10-02 2011-07-27 Genentech, Inc. APO-2 ligand variants and uses thereof
CA2466054C (en) * 2001-11-13 2012-01-03 Genentech, Inc. Apo-2 ligand/trail formulations
CN100500841C (zh) * 2005-10-10 2009-06-17 华东理工大学 一种表达可溶性trail蛋白的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997001633A1 (en) * 1995-06-29 1997-01-16 Immunex Corporation Cytokine that induces apoptosis
WO1997023615A1 (de) * 1995-12-22 1997-07-03 Boehringer Mannheim Gmbh Multimere formen von il-16, verfahren zu ihrer herstellung und verwendung
WO1997025428A1 (en) * 1996-01-09 1997-07-17 Genentech, Inc. Apo-2 ligand

Also Published As

Publication number Publication date
EP2339003A2 (en) 2011-06-29
NZ537920A (en) 2006-10-27
AU2005211561B2 (en) 2008-08-21
KR100674528B1 (ko) 2007-01-29
MXPA01013236A (es) 2002-06-21
IL147029A (en) 2012-02-29
EP2339003A3 (en) 2011-10-19
JP2011088897A (ja) 2011-05-06
CA2377585A1 (en) 2001-01-04
EP1194555B1 (en) 2012-09-26
WO2001000832A9 (en) 2012-03-08
AU2008249162A1 (en) 2008-12-11
IL147029A0 (en) 2002-08-14
ES2392392T3 (es) 2012-12-10
NZ515990A (en) 2003-10-31
US20120077740A1 (en) 2012-03-29
CN1370232A (zh) 2002-09-18
EP2311956A1 (en) 2011-04-20
AU6338200A (en) 2001-01-31
WO2001000832A1 (en) 2001-01-04
US7855066B1 (en) 2010-12-21
US20070161564A1 (en) 2007-07-12
CN101633692A (zh) 2010-01-27
JP5118796B2 (ja) 2013-01-16
AU2005211561A1 (en) 2005-10-13
KR20020016856A (ko) 2002-03-06
JP2003503057A (ja) 2003-01-28
EP1194555A1 (en) 2002-04-10

Similar Documents

Publication Publication Date Title
KR100674528B1 (ko) 2가 금속 이온을 사용한 Ａｐｏ-2 리간드 제조 방법
JP4603023B2 (ja) Ａｐｏ−２リガンド変異体とその使用法
JP4574350B2 (ja) Ａｐｏ−２リガンド／ｔｒａｉｌ変異体とその使用法
RU2435781C2 (ru) Способ очистки аро-2 ligand/trail посредством кристаллизации на холоде
AU2011265480A1 (en) Methods for making APO-2 ligand using divalent metal ions
HK1140780A (en) Methods for making apo-2 ligand using divalent metal ions
AU2002330173A1 (en) Apo-2 ligand variants and uses thereof
AU2011235952A1 (en) APO-2 ligand variants and uses thereof
AU2007201621A1 (en) Apo-2 ligand variants and uses thereof

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20090812